FilingFirehose · free AI preview
Pelthos Therapeutics Inc.
PTHS · AI-generated SEC analysis preview · refreshes when data changes
⚠️ Red flag 8-Ks: 2
Types: Officer Departure
Pelthos Therapeutics Inc. (PTHS) reported two officer departures via 8-K filings in April and May 2026, with no cyber incidents detected in the past 90 days. While leadership turnover is common in biotech, understanding the timing, roles affected, and context around equity compensation is critical for assessing execution risk and potential shareholder dilution. The full $49 Report contextualizes these departures within Pelthos's financing history, burn rate trajectory, and AI-driven risk signals that may not yet be visible in public filings. The full $49 Report adds detailed dilution risk scoring, complete 8-K context analysis, 12-month filing review, and emerging financial stress indicators.
Want the full 5-section $49 Report on PTHS?
Dilution risk score · 12 months of 8-K context · financing history · AI risk signals · bottom-line framing. Delivered in ~5 minutes.
See a real sample report →
This preview was AI-generated from FilingFirehose's SEC EDGAR ingestion pipeline.
Not investment advice. Verify all claims against original filings.